Vnitr Lek 2022, 68(4):253-256 | DOI: 10.36290/vnl.2022.052

Urapidil: an unknown / known antihypertensive

Jiří Slíva
Ústav farmakologie, 3. LF UK, Praha

Essential arterial hypertension is not a disease that would significantly adversely affect patients in their daily activities. At least mostly. Nonetheless, it has a significant negative impact on cardiovascular morbidity and mortality. The tight correlation with the degree of hypertension, the patient's age and, of course, commorbidities and cardiovascular risk factors is obvious. Therefore, the goal of hypertensive therapy is not only to try to achieve optimal reduction of blood pressure, but in a broader sense to reduce the risk of the just mentioned consequences, i.e. to reduce morbidity and reduce mortality. The antihypertensive drug urapidil can also be used in pharmacotherapy, the brief description of which is the subject of this article.

Keywords: urapidil, hypertension, treatment, antihypertensives.

Published: June 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Urapidil: an unknown / known antihypertensive. Vnitr Lek. 2022;68(4):253-256. doi: 10.36290/vnl.2022.052.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur.Heart J 2018; 39: 3021-3104. Go to original source... Go to PubMed...
    2. Buch J. Urapidil, a dual‑acting antihypertensive agent: Current usage considerations. Adv Ther 2010;27:426-443. Go to original source... Go to PubMed...
    3. Langtry HD, Mammen GJ, Sorkin EM. Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1989;38:900-940. Go to original source... Go to PubMed...
    4. Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998;56:929-955. Go to original source... Go to PubMed...
    5. Fariello R, Dal PC, Pessina A et al. Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs 1990;40 Suppl 4:60-62. Go to original source... Go to PubMed...
    6. SPC. Ebrantil retard 30 mg tvrdé tobolky s prodlouženým uvolňováním. Zdroj: www.sukl.cz (posl. přístup 22/01/2022).
    7. Kirsten R, Nelson K, Steinijans VW, Zech K, Haerlin R. Clinical pharmacokinetics of urapidil. Clin Pharmacokinet. 1988 Mar;14(3):129-40. Go to original source... Go to PubMed...
    8. Gerber A, Weidmann P, Marone C et al. Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension 1985;7:963-971. Go to original source... Go to PubMed...
    9. Haerlin R, Engelstratter R, Henze F, Radtke HW. Treatment of primary and secondary hypertension. Long‑term use of urapidil (Ebrantil'P). Clinic al Trials Journal. Clinic al Trials Journal 1985;22:215-223.
    10. Trimarco B, Rosiello G, Feldhaus P et al. Efficacy of once‑daily urapidil treatment in mild or moderate essential hypertension assessed by ambulatory 24-hour blood pressure monitoring. Drugs. 1988;35 Suppl 6:173-181. Go to original source... Go to PubMed...
    11. Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non‑responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl 1995;3:38-46. Go to PubMed...
    12. Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press Suppl. 1995;3:21-5. Go to PubMed...
    13. Alijotas‑Reig J, Bove‑Farre I, de Cabo‑Frances F, Angles‑Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg.Med 2001;19:130-133. Go to original source... Go to PubMed...
    14. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 2002 Dec;17(12):937-45. Go to original source... Go to PubMed...
    15. Souček M, Novák J. Urapidil v léčbě hypertenzní krize Interv Akut Kardiol 2013;12(3):150-152.
    16. Yang W, Zhou YJ, Fu Y et al. Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial. Exp.Ther Med 2016;12:115-122. Go to original source... Go to PubMed...
    17. Yang W, Zhou YJ, Fu Y et al. Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. Yonsei Med J 2017;58:105-113. Go to original source... Go to PubMed...
    18. Shi J, Li Y, Xing C et al. Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta‑analysis. Drug Des Devel.Ther 2019;13:161-172. Go to original source... Go to PubMed...
    19. Carles G, Helou J, Dallah F et al. Utilisation de l'urapidil injectable dans l'hypertension gravidique et la prééclampsie (Use of injectable urapidil in pregnancy‑induced hypertension and preeclampsia). J Gynecol Obstet Biol Reprod (Paris). 2012 Nov;41(7):645-649. Go to original source... Go to PubMed...
    20. Wacker JR, Wagner BK, Briese V et al. Antihypertensive therapy in patients with pre‑eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol. 2006 Aug;127(2):160-165. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.